Our Global Health (GH) division harnesses advances in science and technology to save lives in poor countries. We focus on the health problems that have a major impact in developing countries but get too little attention and funding. Where tools exist, we support sustainable ways to improve their delivery. Where they don’t, we invest in research and development of new interventions, such as vaccines, drugs, and diagnostics. Our work in infectious diseases focuses on strategies to fight and prevent HIV/AIDS, malaria, tuberculosis, neglected tropical diseases, enteric and diarrheal diseases, pneumonia, and maternal, newborn and child health.
Our TB and HIV work is combined under a joint TB/HIV Program Strategy Team (PST), and focuses on research, development and delivery of new products and tools.
The foundation’s Tuberculosis (TB) team aims to address key gaps along the TB care pathway through new approaches to protecting against infection, preventing progression from infection to disease, and improving diagnosis and treatment. Our efforts are diversified based on the understanding that vaccines, diagnostics, drugs, and improved care delivery are all essential to addressing the TB epidemic.
HIV remains a global epidemic that disproportionately impacts some of the most vulnerable populations. While ART scale-up has led to decreased mortality and incidence, there remains a persistently high incidence. The HIV Program’s strategic vision is to accelerate the reduction in the incidence of HIV infection in high-burden geographies and populations, and a main focus for the program is to develop new prevention interventions, including vaccines and biologics and enable their effective use as well as improving access and adherence to treatment.